APA (7th ed.) Citation

SM, S., S, Z., V, S., M, R., JR, A., L, S., . . . S, C. (2022). Physician risk perceptions and surveillance practices for tyrosine kinase inhibitor long-term effects in pediatric CML. Pediatric hematology and oncology, 39(5), 453. https://doi.org/10.1080/08880018.2021.2017085

Chicago Style (17th ed.) Citation

SM, Smith, et al. "Physician Risk Perceptions and Surveillance Practices for Tyrosine Kinase Inhibitor Long-term Effects in Pediatric CML." Pediatric Hematology and Oncology 39, no. 5 (2022): 453. https://doi.org/10.1080/08880018.2021.2017085.

MLA (9th ed.) Citation

SM, Smith, et al. "Physician Risk Perceptions and Surveillance Practices for Tyrosine Kinase Inhibitor Long-term Effects in Pediatric CML." Pediatric Hematology and Oncology, vol. 39, no. 5, 2022, p. 453, https://doi.org/10.1080/08880018.2021.2017085.